Bone Density Changes After Chemotherapy in Children with Bone Sarcoma
Author Information
Author(s): Müller Carsten, Winter Corinna C, Rosenbaum Dieter, Boos Joachim, Gosheger Georg, Hardes Jendrik, Vieth Volker
Primary Institution: University Hospital Münster
Hypothesis
Children and adolescents undergoing treatment for bone sarcomas reveal BMD decrements already after completion of neoadjuvant chemotherapy.
Conclusion
The study found no significant decrements of lumbar spine BMD in pediatric sarcoma patients after chemotherapy, but local osteopenia was observed in the affected extremity.
Supporting Evidence
- Bone density was measured in 46 pediatric patients after chemotherapy.
- No significant decrease in lumbar spine BMD was observed.
- Local osteopenia was noted in the affected extremity.
- The calcaneus showed a more pronounced reduction in BMD compared to the femoral neck.
Takeaway
Kids with bone cancer might lose some bone strength after treatment, especially in the part of the body where the tumor was, but their overall spine strength doesn't seem to change much right after treatment.
Methodology
The study used dual-energy x-ray absorptiometry (DXA) to measure bone mineral density in pediatric patients after chemotherapy.
Potential Biases
Potential biases may arise from the small sample size and the specific treatment protocols followed.
Limitations
The patient group was heterogeneous in terms of age and treatment protocols, and the lack of Tanner stage assessment limits conclusions about puberty's impact on BMD.
Participant Demographics
Participants were 46 children and adolescents aged 8-21 years, all Caucasian, with a mean age of 14.3 years.
Statistical Information
P-Value
0.016
Confidence Interval
95% CI: -0.46 to 0.18
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website